



OPEN

Nitric oxide down-regulates voltage-gated Na⁺ channel in cardiomyocytes possibly through S-nitrosylation-mediated signaling

Pu Wang^{1,3}, Mengyan Wei^{1,3}, Xiufang Zhu^{1,3}, Yangong Liu^{1,3}, Kenshi Yoshimura³, Mingqi Zheng¹, Gang Liu¹, Shinichiro Kume³, Masaki Morishima², Tatsuki Kurokawa³ & Katsushige Ono³✉

Nitric oxide (NO) is produced from endothelial cells and cardiomyocytes composing the myocardium and benefits cardiac function through both vascular-dependent and—independent effects. This study was purposed to investigate the possible adverse effect of NO focusing on the voltage-gated Na⁺ channel in cardiomyocytes. We carried out patch-clamp experiments on rat neonatal cardiomyocytes demonstrating that NOC-18, an NO donor, significantly reduced Na⁺ channel current in a dose-dependent manner by a long-term application for 24 h, accompanied by a reduction of Nav1.5-mRNA and the protein, and an increase of a transcription factor forkhead box protein O1 (FOXO1) in the nucleus. The effect of NOC-18 on the Na⁺ channel was blocked by an inhibitor of thiol oxidation *N*-ethylmaleimide, a disulfide reducing agent disulfide 1,4-Dithioerythritol, or a FOXO1 activator paclitaxel, suggesting that NO is a negative regulator of the voltage-gated Na⁺ channel through thiols in regulatory protein(s) for the channel transcription.

Nitric oxide (NO) is a small gaseous molecule implicated in multiple signal transduction pathways, and is a critical factor in preventing the pathogenesis and progression of cardiovascular diseases heart¹. Recent studies revealed that NO plays an important role in the development of cardiovascular disease^{2,3}. NO is also recognized as a therapeutic drug classified as a vasodilator, and its activity is mediated through stimulation of soluble guanylate cyclase (cGC), which results in formation of the second messenger cyclic guanosine monophosphate (cGMP) and increased activity of protein kinase G (PKG)^{4,5}. Moreover, it is recently clarified that NO is also capable of signaling independent of cGMP, namely via post-translational modulation of protein thiol groups. This redox-sensitive modification is known as protein S-nitrosylation^{6–8}. Although NO-dependent modulation of cardiac function is intensively studied in the past decades in the diseased and failing heart, several aspects of NO signaling in the myocardium remain poorly understood. Some apparently contrasting findings may have arisen from the use of non-isoform-specific inhibitors of NO synthase as compared to the use of experimental models genetically deficient or overexpressing the NO synthase^{9–11}. The challenge is now to highlight these emerging findings on the critical role of NO in cardiac physiology/pathophysiology.

In cardiovascular system many ion channels regulate transmembrane currents that make much contribution to excitation in cardiomyocytes^{12–14}. Among them the voltage-gated Na⁺ channel current (I_{Na}) plays a critical and significant role for the fast upstroke of the action potentials and is essential for proper conduction of the electrical impulse. Voltage-gated sodium channels are composed of a pore-forming α subunit and auxiliary β subunits. SCN5A gene encodes Na_v1.5 protein, the α -subunit of the major cardiac voltage-gated sodium channel. Although several studies have revealed an acute action of NO to induce persistent Na⁺ current in cardiomyocytes^{15,16}, long-term effects of NO on the channel gating and expression of the channel protein are poorly understood. The present study provides novel information that NO is a negative regulator of the voltage-gated Na⁺ channel

¹Department of Cardiology, The First Hospital of Hebei Medical University, 89 Donggang Road, Shijiazhuang 050031, Hebei Province, People's Republic of China. ²Department of Food Science and Nutrition, Faculty of Agriculture, Kindai University, Nara, Japan. ³Department of Pathophysiology, Oita University School of Medicine, Yufu, Oita 879-5593, Japan. ✉email: ono@oita-u.ac.jp




Figure 1. Short- and long-term effects of NOC-18 on Na⁺ channel current (I_{Na}) in neonatal rat cardiomyocytes. **(A)** Representative I_{Na} traces in the control condition and during the acute (5 min) application of 1 mM NOC-18 given to the same patch are shown. I_{Na} was recorded by a depolarization pulse of 50 ms duration, ranging from -80 to 40 mV in 5 mV steps, applied from holding potentials of -140 mV. Current (I)-voltage (V) relationship before (control) and after application of 1 mM NOC-18 (5 min) demonstrates the maximum inward current of the control (-151.2 ± 14.9 pA/pF) and with NOC-18 (-156.2 ± 9.5 pA/pF). **(B)** The steady-state inactivation and activation (conductance) curves of the control and during application of NOC-18 (5 min); Mid-points of the voltage relation for the activation ($V_{a,1/2}$) was -36.0 ± 0.2 mV in the control and -37.1 ± 0.2 mV during application of NOC-18; Midpoint of the voltage relation for the inactivation ($V_{i,1/2}$) was -63.7 ± 0.2 mV in the control and -65.6 ± 0.2 mV during application of NOC-18. **(C)** Representative I_{Na} traces with vehicle or NOC-18 treated for 24 h. I-V relationship demonstrates the maximum inward current of vehicle (-160.7 ± 11.6 pA/pF, $n = 18$) and with NOC-18 (-122.2 ± 10.9 pA/pF). **(D)** The steady-state inactivation and activation (conductance) curves of vehicle (24 h) and NOC-18 (24 h); $V_{a,1/2}$ was -39.0 ± 0.2 mV in vehicle and -37.4 ± 0.2 mV in NOC-18 (24 h); $V_{i,1/2}$ was -65.3 ± 0.2 mV in vehicle and -73.8 ± 0.4 mV in NOC-18 (24 h). Values represent the mean \pm SE. Numbers of cell are shown in parentheses. * $p < 0.05$ vs. vehicle.

possibly through S-nitrosylation pathway in regulatory proteins including forkhead box protein O1 (FOXO1) for the channel transcription.

Results

Long-term effects of an NO donor NOC-18 on I_{Na}. In conventional whole-cell patch-clamp experiments using rat neonatal cardiomyocytes, I_{Na} was recorded. Figure 1A shows representative I_{Na} families in the control condition and during the acute action of an NO donor, 2,2'-(hydroxynitrosohydrazino)-bis-ethanamine (NOC-18), for 5 min. Group data indicate that NOC-18 has substantially no acute effect (< 5 min) on I_{Na} as indicated by the current (I)-voltage (V) relationship (Fig. 1A), and the activation (conductance) and the steady-state inactivation curves (Fig. 1B). On the other hand, long-term treatment of cardiomyocytes with 1 mM NOC-18 for 24 h reduced I_{Na} by 26% when assessed by the maximum inward current (Fig. 1C). To determine the effect of NOC-18 on the activation and steady-state inactivation kinetics of I_{Na}, the fractional I_{Na} and fractional Na⁺ channel conductance were compared in cardiomyocytes with or without NOC-18 treatment. Treatment of cardiomy-




Figure 2. Concentration-dependent long-term (24 h) effects of NOC-18 and S-Nitroso-N-acetyl-DL-penicillamine (SNAP) on I_{Na} . **(A)** Representative I_{Na} traces with vehicle, 100 μ M SNAP, 300 μ M SNAP and 1000 μ M SNAP applied for 24 h. **(B)** Dose–response relationships of the effects of NO donors, NOC-18 and SNAP, on the fractional I_{Na} . The potency, e.g. half-maximum inhibitory concentration (IC_{50}), was estimated as 491 μ M and 1505 μ M for SNAP and NOC-18, respectively. Numbers of cell are shown in parentheses.

ocytes with 1 mM NOC-18 for 24 h had no significant effect on the voltage dependency of the activation curve, which is consistent with the result in Fig. 1C. However, the steady-state inactivation curve was significantly shifted in the direction of hyperpolarization by 8.5 mV by a long-term treatment with 1 mM NOC-18 (Fig. 1D).

Dose–response effect of NO donors on I_{Na} suppression. NOC-18 is a diazeniumdiolate analogue with an action of releasing NO¹⁷. In order to further confirm the action of NO to suppress I_{Na} , we have attempted to observe the changes of I_{Na} with a different NO donor without a chemical structure of diazeniumdiolate. S-nitroso-n-acetyl penicillamine, SNAP, is an NO donor with a chemical structure of S-nitrosothiol. Although an acute application of SNAP (300 μ M) for 5 min was without effect on I_{Na} , treatment of cardiomyocytes with SNAP (300–1000 μ M) for 24 h decreased I_{Na} in a dose-dependent manner (Fig. 2A). The half maximal inhibitory concentration (IC_{50}) of NOC-18 and SNAP to reduce I_{Na} was 1410 μ M and 502 μ M, respectively (Fig. 2B).

Effects of NO scavenger. There is considerable evidence indicating that NO metabolism involves a family of NO-treated molecules in addition to nitrate and nitrite ions. Carboxy-PTIO, carboxy-2-phenyl-4,4,5,5-tetra-methylimidazole-1-oxyl-3-oxide potassium, is a potent NO inhibitor that can make a quick reaction with NO to produce NO₂¹⁸. Application of carboxy-PTIO to cardiomyocyte without NOC-18 displayed no appreciable effects on I_{Na} . Importantly, NOC-18 (1 mM) was without effect on I_{Na} when cardiomyocytes were co-treated with carboxy-PTIO for the same duration of 24 h (Fig. 3A,B). These results suggest that NOC-18 exerts its effect on I_{Na} mostly through action of NO but not through other metabolites or reactive nitrogen intermediates.

We evaluated protein thiols as an effector target reflecting NOC-18-dependent regulation of I_{Na} in cardiomyocytes. N-ethylmaleimide (NEM) is a compound that forms stable, covalent thioether bonds with sulfhydryls, enabling them to be permanently blocked to prevent disulfide bond formation¹⁹; a potent inhibitor of S-nitrosylation as it irreversibly reacts with and binds to sulfhydryl groups thereby preventing NO from engaging in an S-nitrosylation reaction. In the presence of NEM, NOC-18 was unable to reduce I_{Na} when applied for 24 h (Fig. 4A,B). 1,4-Dithioerythritol (DTE) is a strong reducing agent for the quantitative reduction of disulfide groups and cleavage of disulfide bridges in proteins²⁰. Likewise, NOC-18 was unable to reduce I_{Na} when applied for 24 h in the presence of DTE (Fig. 4C,D). These results strongly indicate that NO is a negative regulator of cardiac voltage-gated Na channel through thiols in protein(s) possibly responsible for the Na⁺ channel transcription, trafficking or maturation.

Protein kinase G and S-nitrosylation of thiols. The existence of two effector pathways of NO, NO/cGMP/PKG signal cascade and NO/S-nitrosylation dependent signal pathway, has important functional implications on cardiovascular system. To clarify the mechanism of NOC-18 for I_{Na} modulation, we have applied NOC-18 in the presence of a protein kinase G inhibitor KT5823 (Fig. 5A,B). The reduction of I_{Na} by NOC-18 occurred even when cardiomyocytes were incubated with KT5823. Importantly, reduction rate of I_{Na} by NOC-18 in the presence of KT5823 (29%) was nearly identical to those without KT5823 (26%) in Fig. 1, indicating that effect of NO on I_{Na} suppression is independently of the signal pathway caused by cGMP/PKG. This observation was also confirmed by the experiment by use of a guanylate cyclase inhibitor 1H-1,2,4-oxadiazolo[4,3-a]quinoxalin-1-one (ODQ); reduction of I_{Na} by NOC-18 was unmasked by ODQ (Fig. 5C,D). Furthermore, a membrane permeable cGMP analogue, 8-Bromo-cGMP (8Br-cGMP), had no effect on I_{Na} (Fig. 6), which firmly supports the conclusion that GC/cGMP/PKG signaling pathway is not involved in NOC-18-induced long-term inhibition of I_{Na} .




Figure 3. Effects of an NO scavenger carboxy-PTIO (20 μ M) on the action of NOC-18 for I_{Na} modulation. (A) Representative I_{Na} traces in the control condition (vehicle), 20 μ M carboxy-PTIO, and 20 μ M carboxy-PTIO plus 1 mM NOC-18 applied for 24 h. (B) I - V relationship of I_{Na} with vehicle, 20 μ M carboxy-PTIO, and 20 μ M carboxy-PTIO plus 1 mM NOC-18, demonstrating no statistical difference among three groups. Numbers of cell are shown in parentheses. Values represent the mean \pm SE.




Figure 4. Effects of a sulfhydryl-reducing agent *N*-ethylmaleimide (NEM) and a thiol-reducing agent dithiothreitol (DTE) on NOC-18 for I_{Na} modulation. (A,B) Representative I_{Na} traces with 1 mM NOC-18 applied for 24 h in the absence or presence of NEM, and their I - V relationships of I_{Na} . (C,D) Representative I_{Na} traces with 1 mM NOC-18 applied for 24 h in the absence or presence of DTE, and their I - V relationships of I_{Na} . In the presence of NEM or DTE, NOC-18 was unable to reduce I_{Na} . Numbers of cell are shown in parentheses. Values represent the mean \pm SE.




Figure 5. Effects of a PKG inhibitor KT5823 and a guanylate cyclase inhibitor ODQ on NOC-18 for I_{Na} modulation. **(A,B)** Representative I_{Na} traces with 1 mM NOC-18 applied for 24 h in the absence or presence of 500 nM, and their I–V relationships of I_{Na} . In the presence of KT5823, NOC-18 reduce the maximum inward current of I_{Na} by 31%, indicating that I_{Na} inhibiting effects of NOC-18 was independently of the action through PKG. **(C,D)** Representative I_{Na} traces with 1 mM NOC-18 applied for 24 h in the absence or presence of 10 μ M ODQ, and their I–V relationships of I_{Na} . In the presence of ODQ, NOC-18 reduced the maximum inward current of I_{Na} by 35%, indicating that I_{Na} inhibiting effects of NOC-18 was independently of the action through GC activity. Numbers of cell are shown in parentheses. Values represent the mean \pm SE. * $p < 0.05$ vs. KT5823 + NOC-18 or vs. ODQ + NOC-18.

Possible interaction with a transcriptional regulator FOXO1. NO modulation of I_{Na} may be caused by inhibition of the channel synthesis, which includes regulation of mRNA transcription and protein expression. Therefore we did real-time RT-PCR quantification of the cardiac Na^+ channel genes, *SCN5A*, using mRNA samples extracted from cardiomyocytes treated with or without NO donors for 24 h. As shown in Fig. 7A, the mRNA levels were significantly reduced by NO donors, SNAP and NOC-18. Hydrogen peroxide (H_2O_2) is a positive control which is known to reduce *SCN5A* and increase a transcription factor forkhead box protein O1 (FOXO1) in cardiomyocytes²¹. In contrast to *SCN5A*, FOXO1 mRNA was unchanged by SNAP or NOC-18 (Fig. 7A). We then carried out Western blot analysis of the Na^+ channel and FOXO1 proteins isolated from neonatal rat cardiomyocytes. Figure 7B demonstrates that 1 mM NOC-18 reduced Nav1.5 protein expression by 34% (n=4), and increased FOXO1 protein by 70% (n=4) in the nucleus. In consistent with this result, a FOXO1 activator paclitaxel, applied for 24 h, significantly decreased I_{Na} : the maximum inward current of I_{Na} was reduced by 36% (Fig. 7C,D). When NOC-18 was applied with paclitaxel, I_{Na} was reduced by 36%, which was identical to those of paclitaxel (Fig. 7C,D). We note that the reduction ratio of the maximum inward current of I_{Na} by 1 mM NOC-18 alone was 26% (Fig. 1C). Taken together with this reduction ratio, it is suggested that NOC-18 is without effect on I_{Na} when FOXO1 is highly activated. Furthermore, immunocytochemistry staining revealed that NOC-18 exhibited disarrangement and suppression of Nav1.5 protein accompanied by a perinuclear aggregation of FOXO1 protein in cardiomyocytes (Fig. 7E). Thus, these results lead to the conclusion that decreased




Figure 6. Effects of a membrane-permeable analog of cGMP (8Br-cGMP) on I_{Na} . **(A, B)** Representative I_{Na} traces with vehicle and 500 μ M 8Br-cGMP applied for 24 h, and their I–V relationships of I_{Na} . 8Br-cGMP was unable to modify I_{Na} . Numbers of cell are shown in parentheses. Values represent the mean \pm SE.

Nav1.5 protein levels by NOC-18 may be due to the modulation of FOXO1 activity as a repressor to inhibit the transcription of SCN5A in cardiomyocytes.

Discussion

The present study demonstrates a novel NO-dependent modulatory mechanism that alters the voltage-gated Na^+ channel protein Nav1.5 and thereby I_{Na} in neonate cardiomyocytes. Although NO is recognized as a potent vasodilator, and its activity is highly beneficial for the ischemic heart, this investigation provides a surprising new dimension to NO signaling which is the cGMP-independent action of NO to down-regulate the Na^+ channel through S-nitrosylation. The major findings of this investigation are summarized as follows: (1) Long-term but not short-term application of NO donors, NOC-18 and SNAP, reduced I_{Na} in a dose-dependent manner; (2) an NO donor NOC-18 shifted the steady-state inactivation curve, but not the activation curve, to the hyperpolarization direction; (3) a potent NO inhibitor Carboxy-PTIO masks the effect of NOC-18 on I_{Na} ; (4) a GC inhibitor ODG and a PKG inhibitor KT5823 could not block the effect of NOC-18 on I_{Na} ; (5) a membrane permeable cGMP (8 Br-cGMP) was without effect on I_{Na} ; (6) protein thiol modulation inhibitors, NEM and DTE, suppressed the effect of NOC-18 on I_{Na} ; (7) NOC-18 decreased the protein expression of Nav1.5 channel, and increased the expression of a transcription factor FOXO1 in the nucleus; (8) NOC-18 was without effect on I_{Na} when FOXO1 was highly activated by a FOXO1 activator paclitaxel, and (9) immunocytochemistry staining revealed that NOC-18 suppressed Nav1.5 protein expression accompanied by a perinuclear aggregation of FOXO1 protein. These findings suggest a novel action of NO on the voltage-gated Na^+ channel through S-nitrosylation pathway, which could be adverse to cardiac function particularly in the diseased conditions of the heart.

NO is produced from virtually all cell types composing the myocardium, and regulates cardiac function through vascular-dependent and—independent manners. The role of NO in cardiac function is complex and controversial²². NO can bind to GC, increasing cGMP production and activate PKG. NO may also directly S-nitrosylate cysteine residues of specific proteins. In this context, it is particularly important to elucidate molecular targets of NO, or NO donors NOC-18 and SNAP in this experiment. For voltage-gated ion channels, targets of PKG include Ca^{2+} -activated K^+ channel²³, ATP-sensitive K^+ channel²⁴, voltage-gated L, N, T-type Ca^{2+} channel^{25,26}, and voltage-gated Na^+ channels²⁷ with their respective impact on cellular excitability. In addition, S-nitrosylation of cysteine residues has emerged as an important feature of NO signaling. Though this post-translational modification, NO is able to regulate the function of ion channels including, Ca^{2+} activated K^+ channel²⁸, voltage-gated L-type Ca^{2+} channel²⁹, cyclic nucleotide gated channel³⁰, and voltage-gated Na^+ channels^{4,31}. In addition to these emerging evidence linking PKG/S-nitrosylation to the voltage-gated Na^+ channel by regulating the state of post-translational modulation, this investigation, for the first time, shed light on the transcriptional effects of NO on the cardiac Na^+ channel.

In the present study NOC-18 and SNAP were used as NO donors. It has been reported that NO released from 1 mM NOC-18 results in steady-state levels of 1–5 μ M NO in medium without any cofactors³². This is comparable to concentrations (1–30 μ M) produced by endogenous inducible NO synthase in culture media and in plasma after cytokine stimulation or lung injury³³. For the clinical setting of NO for the treatment of pulmonary hypertension, acute lung injury, and cardiopulmonary failure, concentration of 15–30 ppm (5–10 μ M) of NO has widely been applied³⁴. During these clinical applications of NO, lung endothelium and cardiomyocytes are exposed to be exposed to the same concentration or slightly lower than that in the inhaled NO gas. Thus exposure of cardiomyocytes to 1–5 μ M NO constitutes a pathophysiologically relevant cellular model with which to study NO-mediated modulation of ion channels in cardiomyocytes. Cultured neonatal cardiomyocytes were exposed to 1 mM NOC-18 for 24 h in this investigation. Therefore results in this study imply that NO plays an important role in regulation of myocardial Na^+ channel during clinical therapeutic application of NO or NO donor in vivo.




Figure 7. FOXO1 as a possible link between NO and Nav1.5. **(A)** Changes of SCN5A mRNA- and FOXO1 mRNA-expression were examined by NO donors SNAP and NOC-18. SNAP (500 μM) and NOC-18 (1 mM) significantly reduced mRNA levels of SCN5A, although both NO donors were without effects on FOXO1 mRNA levels. Effects of 25 μM H₂O₂ were assessed as positive controls. **(B)** Effects of NOC-18 on SCN5A and FOXO1 protein expression evaluated by Western blot analysis. Nav1.5 protein levels (whole cell) were significantly reduced, whereas FOXO1 protein levels (nucleus) were significantly increased by 1 mM NOC-18 applied for 24 h. Numbers of sample are shown in parentheses. Data were expressed as mean ± SD. **p* < 0.05. See the supplemental file for the complete gel/blot images. **(C,D)** Actions of a FOXO1 activator paclitaxel and NOC18 for I_{Na}. **(C)** Representative I_{Na} traces with vehicle, 1 μM paclitaxel and 1 μM paclitaxel with 1 mM NOC-18 applied for 24 h, and **(D)** their I–V relationships. Numbers of cell are shown in parentheses. **(E)** Expression and distribution of Nav1.5 and FOXO1 as assessed by immunocytochemistry procedure. Cardiomyocytes were exposed to vehicle or 1 mM NOC-18 for 24 h. Nav1.5 for stained in green, FOXO1 in red, and DAPI staining to visualize nuclei in blue. Scale bar = 20 μm.

Although our study could not detect the acute effects of NO donor on I_{Na} , previous several studies identified NO/cGMP/PKG pathway to regulate I_{Na} as a short-term effect^{16,27,35}. Because the life span of NO in blood milieu or in the bathing solution is less than 0.2 ms³⁰, biological exposure time of NO largely depends on the NO-releasing speed of NO donor. NOC-18 is a diazeniumdiolate slow-releasing NO donor with a half-life for NO release of 20 h, where the rate of release is attributed to the structure³⁶. NOC-18 is an ideal NO donor since the amine byproduct formed has no known interferences with cellular activities. Therefore, unlike experiments using gaseous NO to obtain saturated concentration of NO in the medium, experiments by use of a slow-releasing NO donor NOC-18 are suitable to assess the possible transcriptional effect of NO to cardiomyocytes. In this context, we could not observe persistent Na^+ current in this experiments, presumably because increases of NO concentration by slow-releasing NO donors were neither prompt and high enough in the bath medium for the electrophysiological studies. Also as a limitation of whole-cell patch clamp experiments, in most patch clamp amplifier in the market, leak subtraction could subtract the leak current produced by single depolarizing pulse but not the leak current produced by a series of different step depolarizing pulses. Due to its assumption that leak current would be produced if only potential difference arises across membrane, recording protocols in manufactured voltage-clamp program by use of leak subtraction are not suitable to subtracting the steady-state leak current while recording voltage-gated channel currents which is also time-dependently altered.

Several studies, particularly based on plants with altered NO levels, have recently provided genetic evidence for the importance of NO in gene induction^{37,38}, although little is known on the role of NO as a regulator of gene expression in mammals. Furthermore, the NO-dependent intracellular signaling pathway(s) that lead to the activation or suppression of these genes have not yet been defined. In this context, for the first time, our study has revealed a novel role of NO as a positive modulator of FOXO1 in cardiomyocytes, leading to a reduction of Nav1.5 proteins. Because FOXO1-mRNA was unchanged and phosphorylated form of FOXO1 was increased in the nucleus in response to NO (Fig. 7A,B), and because NOC-18 suppressed Nav1.5 protein expression accompanied by a perinuclear aggregation of FOXO1 protein (Fig. 7E), it is suggested that FOXO1 translocates from the cytoplasm to the nucleus and suppresses the expression of Nav1.5. Phosphorylated Foxo1 can be dephosphorylated by phosphatase allowing Foxo1 to enter the nucleus³⁹. Therefore functional modulation or stimulation of phosphatase by NO-mediated S-nitrosylation is possibly postulated, although we have no data to support this speculation. Obviously a complete transcriptome analysis is needed for the understanding about the mechanism of NO-mediated Nav1.5 suppression.

Derangement of NO production regulation, such as produced on excessive NO delivery from inflammatory cells (or cytokine-stimulated cardiomyocytes themselves), may result in profound cellular disturbances leading to heart failure⁴⁰. At the same time, however, the functional consequences of altered NO synthase expression and NO bioavailability in the failing heart are poorly characterized. Namely, quite a few numbers of diverse and often contradictory effects of NO and NO donors on myocardial function have been reported. It is widely accepted that NO could modulate inotropic, chronotropic, and dromotropic response to β adrenoceptor stimulation: low dose enhances and high dose reduce β adrenergic response⁴¹. Interestingly, an action of NO to modulate β adrenergic inotropic responses in humans *in vivo* could only be demonstrated in patients with heart failure and not in “normal” subjects⁴². In relation to the action of NO to heart failure, we note the possible adverse effect of NO in patients with diseased heart. In human study, prolonged nitrate treatment was reportedly not beneficial for patients with myocardial infarction^{43,44} and heart failure⁴⁵.

Although we have successfully demonstrated that NO down-regulates I_{Na} in neonatal cardiomyocytes, and have postulated a possible FOXO1-dependent signaling pathway for the regulation of Nav1.5 (Fig. 8), we still need to identify interactor molecules between NO and FOXO1 transcription. As limitation of this investigation, it is also important to keep in mind that reduction of I_{Na} and the sodium channel protein was confirmed by NO donors in *in-vitro* experiments but not in *in-vivo* condition of the heart. Because physiological actions of NO in the heart are largely dependent on the vascular and neuronal regulation of the circulation, drug actions on cardiomyocytes without systemic circulation may not accurately represent the clinical pharmacological effects of NO. Furthermore, we are not sure whether NO donors mimic endogenous NO-related response in the heart. In addition, we could not explore the action of NO on the accessory proteins of the channel including $\beta 1$ and $\beta 2$ subunits, which may affect the gating properties of the channel; e.g. the shift of the steady-state inactivation curve to the hyperpolarization direction. Furthermore, this study is largely dependent upon electrophysiological evaluation of I_{Na} . Therefore, molecular biological analyses for S-nitrosylation substitutes or interactor molecules, quantitative FOXO1 activity, potentially interacted transcription factors besides FOXO1, and mechanisms of FOXO1 nuclear translocation were not performed. Thus, obviously future studies are needed to address these questions.

We conclude that NO is a negative modulator of the voltage-gated Na^+ channel in cardiomyocytes. A significant reduction of I_{Na} as well as the SCN5A protein is considered to be one of mechanisms possibly related to NO-induced cardiac dysfunction particularly in heart failure. The endogenous mechanisms of transcriptional regulation of SCN5A in cardiomyocytes are largely unknown. We also demonstrate in this study that increase of a transcription factor FOXO1 in the nucleus is the trigger for the down-regulation of SCN5A in NO-treated cardiomyocytes. These findings indicate that many diverse and often contradictory effects of NO or NO donor on myocardial function could be attributed to the conduction defect and/or arrhythmias in the heart, at least in a part, caused by a reduction of the voltage-gated Na^+ channel.

Methods

Neonatal rat cardiomyocytes: preparations and culture. All experimental protocols were approved in advance by the Ethics Review Committee for Animal Experimentation of Oita University School of Medicine (No. 1704001, No. 1704002), and were carried out according to the guidelines for animal research of the Physi-




Figure 8. The current hypothesis regarding NO-mediated downregulation of the Na⁺ channel. NO is suggested to act through a suppressor gene FOXO1 for SCN5A transcription. FOXO1*: activated form of FOXO1.

ological Society of Japan to minimize the number of animals used as well as their suffering. Neonatal cardiomyocytes were prepared from 1- to 3-day old Wistar rats as described previously⁴⁶. The cardiomyocytes were plated onto 35-mm culture dishes and cultured in Dulbecco's Modified Eagle's Medium, supplemented with 5% fetal bovine serum at 37 °C under 5% CO₂. The cells were seeded onto glass-bottom dishes and incubated in a culture medium for 24–48 h before electrophysiological measurements.

Electrophysiological measurements. Macroscopic Na⁺ channel currents were recorded in whole cell configuration using an EPC-9 amplifiers (HEKA Elektronik, Lambrecht, Germany) at room temperature (20–23 °C) as described previously⁴⁷. Patch pipettes were pulled from 75-mm plain capillary tubes (Drummond Scientific Co., Broomall, PA, USA) with a micropipette puller, Model P-97 (Sutter Instrument, Co., Novato, CA, USA), and were fire-polished subsequently. The electrode had a resistance of 1.5–2.5 MΩ when the pipette was filled with the pipette solution (see below). Series resistance was compensated electrically as much as possible without oscillation (60–75%). Capacitive artifacts were minimized by using the built-in circuitry of the amplifier. The current signals were filtered at 3.3 kHz and digitized at 10 kHz under the control of a data acquisition program, Pulse/Pulsefit (V.8.11, HEKA Elektronik). To investigate the channel availability (steady-state inactivation), a conventional double-pulse protocol was applied every 2 s: 50 ms of test pulses at –10 mV following 200 ms of prepulses from –140 to –10 mV (increment = 5 mV) were applied. The reversal potential and the chord conductance were calculated by fitting the current–voltage (I–V) relationship to a Boltzmann distribution function: $I = G_{\max} (V_m - V_{\text{rev}}) / (1 + \exp[(V_m - V_{a, 1/2})/k])$, where I is the peak I_{Na} at the given test potential V_m , V_{rev} is the reversal potential, G_{\max} is the maximal chord conductance, $V_{a, 1/2}$ is the half-point of the relationship and k is the slope factor. The voltage-dependent inactivation was similarly determined with a Boltzmann equation: $I/I_{\max} = 1 / (1 + \exp[(V_m - V_{i, 1/2})/k])$, where V_m is the membrane potential, $V_{i, 1/2}$ is the half-point of the relationship and k is the slope factor. The recording chamber was filled with the bath solution of the following components (mM): NaCl 30, MgCl₂ 0.5, TEA-Cl 125, CsCl 5, 4-AP 5, DIDS 0.1, HEPES 10, glucose 10, CaCl₂ 1.8 (pH of 7.4 adjusted with 1 N TEA-OH). The patch-clamp electrode was filled with the pipette solution of (mM): CsF 20, CsCl 120, EGTA 2, HEPES 5, (pH of 7.2 adjusted with 1 N CsOH). The data were acquired by using computer software (Pulse/Pulsefit, V.8.11), and all curve fittings were made on SigmaPlot (V10.0, SPSS Inc., Chicago, IL, USA).

Quantitative real-time RT-PCR. Total RNA was extracted from rat neonatal cardiomyocytes by using TRIzol (Invitrogen, Carlsbad, CA) 24 h after the treatment with agents as described previously⁴⁸. The cDNA was synthesized from 1 mg of total RNA by using Transcriptor First Strand cDNA Synthesis Kit (Roche Molecular System Inc., Alameda, CA, USA). The real-time PCR was performed on Light Cycler (Roche) by using the FastStart DNA Master SYBR Green I (Roche) as a detection reagent. The sequences of the specific primers

were; (SCN5A; KM373692) forward 5'-caggtcggaaacttggtcttcac-3' and reverse 5'-ggaacgcagcacagaca-3'; (Foxo1; NM_019739) forward 5'-ctcccgtactctctgctg-3' and reverse 5'-gtggtcagtggtgactggtt-3'; (GAPDH; GU214026) forward 5'-ccaccagaagactgtggat-3' and reverse 5'-cacattggggtaggaacac-3'. Data were calculated by $2^{-\Delta\Delta CT}$ and presented as fold change in transcripts for SCN5A and Foxo1 genes and normalized to GAPDH (defined as 1.0-fold).

Western blot analysis. Western blot analysis was performed as described previously⁴⁹. Cells were rinsed with phosphate-buffered saline (PBS) twice, and protein was extracted in cold whole cell lysis buffer (Cell Signaling, Beverly, MA). For preparation of nuclear extracts, cells were washed twice with ice-cold PBS, scrapped, and transferred to a centrifuge tube. Nuclear protein from cardiomyocytes were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents based on the manufacturer's instruction (Pierce, Rockford, IL). The extracted protein concentration was determined by the BCA protein assay kit (Pierce, Rockford, IL). Forty μ g of protein samples was loaded on equal protein basis, separated on a 10% SDS-PAGE and transferred from the gel to a PVDF membrane (Hybond-P; GE Healthcare Bio-Sciences, Piscataway, NJ, USA). The membrane was blocked by using 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 for 1 h and then incubated with the indicated primary antibody overnight at 4 °C. The primary antibodies used were as follows: rabbit anti-Foxo1 polyclonal (Cell Signaling, 1:1000), rabbit anti-Nav_v1.5 polyclonal (Alomone Labs Ltd., Jerusalem, Israel, 1:200). The blot was visualized with anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (1:2000, American Qualex, CA) and an ECL plus Western Blotting Detection System (GE Healthcare Bio-Sciences) by using the Image Quant LAS 4000 mini (GE Healthcare GE Healthcare Bio-Sciences) imaging system. Densitometric analysis of each band was carried out using ImageJ software (Wayne Rasband, National Institutes of Health). Protein loading was controlled by probing Western blots with anti- β -actin (1:1000, Cell Signaling) and normalizing Nav_v1.5 and Foxo1 protein band intensities to β -actin values.

Immunocytochemistry. The details of the experiments protocol were performed as described previously⁵⁰. Primary antibodies against Foxo1 (1:200, Cell Signaling, Beverly, MA, USA) and Nav1.5 (1:200, Alomone Labs Ltd., Jerusalem, Israel) were applied following by incubation with the appropriate fluorescence-labeled secondary antibodies (Invitrogen) for 1 h at room temperature. After several washes, the samples were air-dried, mounted with a drop of ProLong Diamond Antifade Mountant with DAPI (Molecular Probes) and subjected to microscopy. Images were obtained with a confocal microscope system (A1R, Nikon, Tokyo, Japan) equipped with a PlanFluor 60X objective lens and excitation lasers (488 and 561 nm, Melles Griot). Images were saved in TIFF format and analyzed by ImageJ software (Wayne Rasband, National Institutes of Health).

Data analysis. IC₅₀ values were estimated using least squares linear regression programmed in SigmaPlot (V10.0, SPSS Inc.). The group data show means \pm SE or SD. Between groups and among groups comparisons were conducted and evaluated by a Tukey–Kramer test, and between two groups, a Brunner–Munzel test was used. $p < 0.05$ was considered statistically significant.

Drugs. All other chemicals were purchased from Wako Chemical Co., Osaka, Japan.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Received: 26 January 2021; Accepted: 18 May 2021

Published online: 28 May 2021

References

- Tamargo, J., Caballero, R., Gómez, R. & Delpón, E. Cardiac electrophysiological effects of nitric oxide. *Cardiovasc. Res.* **87**, 593–600 (2010).
- Sekiya, K. *et al.* Carbon monoxide poisoning-induced delayed encephalopathy accompanies decreased microglial cell numbers: Distinctive pathophysiological features from hypoxemia-induced brain damage. *Brain Res.* **1710**, 22–32 (2019).
- Andreadou, I. *et al.* The role of gasotransmitters NO, H₂S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. *Br. J. Pharmacol.* **172**, 1587–1606 (2015).
- Ahern, G. P., Klyachko, V. A. & Jackson, M. B. cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. *Trends Neurosci.* **25**, 510–517 (2002).
- González, D. R. *et al.* Differential role of S-nitrosylation and the NO-cGMP-PKG pathway in cardiac contractility. *Nitric Oxide* **18**, 157–167 (2008).
- Gonzalez, D. R., Treuer, A., Sun, Q. A., Stamler, J. S. & Hare, J. M. S-Nitrosylation of cardiac ion channels. *J. Cardiovasc. Pharmacol.* **54**, 188–195 (2009).
- Murphy, E. *et al.* Signaling by S-nitrosylation in the heart. *J. Mol. Cell. Cardiol.* **73**, 18–25 (2014).
- Treuer, A. V. & Gonzalez, D. R. Nitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities. *Mol. Med. Rep.* **11**, 1555–1565 (2015).
- Jones, S. P. *et al.* Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. *Proc. Natl. Acad. Sci. USA* **100**, 4891–4896 (2003).
- Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B. & Kass, D. A. Nitric oxide synthases in heart failure. *Antioxid. Redox. Signal.* **18**, 1078–1099 (2013).
- Yano, M. *et al.* Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. *Circulation* **112**, 3633–3643 (2005).
- Lin, C. *et al.* Cross-talk between β_1 -adrenoceptors and ET_A receptors in modulation of the slow component of delayed rectifier K⁺ currents. *Naunyn Schmiedeberg's Arch Pharmacol.* **371**, 133–140 (2005).

13. Fujita, T., Umemura, M., Yokoyama, U., Okumura, S. & Ishikawa, Y. The role of Epac in the heart. *Cell Mol Life Sci.* **74**, 591–606 (2017).
14. Sunagawa, M. *et al.* Electrophysiologic characteristics of atrial myocytes in levo-thyroxine-treated rats. *Thyroid* **15**, 3–11 (2005).
15. Hammarström, A. K. & Gage, P. W. Nitric oxide increases persistent sodium current in rat hippocampal neurons. *J. Physiol.* **520**, 451–461 (1999).
16. Ahern, G. P., Hsu, S. F., Klyachko, V. A. & Jackson, M. B. Induction of persistent sodium current by exogenous and endogenous nitric oxide. *J. Biol. Chem.* **275**, 28810–28815 (2000).
17. Shibuta, S., Mashimo, T., Zhang, P., Ohara, A. & Yoshiya, I. A new nitric oxide donor, NOC-18, exhibits a nociceptive effect in the rat formalin model. *J. Neurol. Sci.* **141**, 1–5 (1996).
18. Goldstein, S., Russo, A. & Samuni, A. Reactions of PTIO and carboxy-PTIO with $\cdot\text{NO}$, $\cdot\text{NO}_2$, and $\text{O}_2\cdot^-$. *J. Biol. Chem.* **278**, 50949–50955 (2003).
19. Ellis, R. J. The use of N-ethylmaleimide in stabilizing and measuring inorganic sulphur compounds. *Biochem J.* **110**, 43P (1968).
20. Lo, S. *et al.* Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism. *J. Steroid Biochem. Mol. Biol.* **84**, 569–576 (2003).
21. Mao, W. *et al.* Reactive oxygen species suppress cardiac NaV15 expression through Foxo1. *PLoS ONE* **7**, e32738 (2012).
22. Cotton, J. M., Kearney, M. T. & Shah, A. M. Nitric oxide and myocardial function in heart failure: friend or foe?. *Heart* **88**, 564–566 (2002).
23. Taniguchi, J., Furukawa, K. I. & Shigekawa, M. Maxi K⁺ channels are stimulated by cyclic guanosine monophosphate-dependent protein kinase in canine coronary artery smooth muscle cells. *Pflügers Arch.* **423**, 167–172 (1993).
24. Han, J., Kim, N., Kim, E., Ho, W. K. & Earm, Y. E. Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes. *J. Biol. Chem.* **276**, 22140–22147 (2001).
25. Hirooka, K., Kourennyi, D. E. & Barnes, S. Calcium channel activation facilitated by nitric oxide in retinal ganglion cells. *J. Neurophysiol.* **83**, 198–206 (2000).
26. Kawai, F. & Miyachi, E. Modulation by cGMP of the voltage-gated currents in newt olfactory receptor cells. *Neurosci. Res.* **39**, 327–337 (2001).
27. Ahmmed, G. U. *et al.* Nitric oxide modulates cardiac Na⁺ channel via protein kinase A and protein kinase G. *Circ. Res.* **89**, 1005–1013 (2001).
28. Shin, J. H., Chung, S., Park, E. J., Uhm, D. Y. & Suh, C. K. Nitric oxide directly activates calcium-activated potassium channels from rat brain reconstituted into planar lipid bilayer. *FEBS Lett.* **415**, 299–302 (1997).
29. Campbell, D. L., Stampler, J. S. & Strauss, H. C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. *J. Gen. Physiol.* **108**, 277–293 (1996).
30. Broillet, M. C. & Firestein, S. Direct activation of the olfactory cyclic nucleotide-gated channel through modification of sulfhydryl groups by NO compounds. *Neuron* **16**, 377–385 (1996).
31. Cheng, J. *et al.* Caveolin-3 suppresses late sodium current by inhibiting nNOS-dependent S-nitrosylation of SCN5A. *J. Mol. Cell Cardiol.* **61**, 102–110 (2013).
32. Bal-Price, A. & Brown, G. C. Nitric-oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondria. *J. Neurochem.* **75**, 1455–1464 (2000).
33. Okamoto, I. *et al.* Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. *Am. J. Respir. Crit. Care Med.* **162**, 716–722 (2000).
34. Barzaghi, N. *et al.* ECMO and inhaled nitric oxide for cardiopulmonary failure after heart retransplantation. *Ann. Thorac. Surg.* **63**, 533–535 (1997).
35. Ikeda, M. & Yoshino, M. Nitric oxide augments single persistent Na⁺ channel currents via the cGMP/PKG signaling pathway in Kenyon cells isolated from cricket mushroom bodies. *J. Neurophysiol.* **120**, 720–728 (2018).
36. Nagababu, E. & Rifkind, J. M. Measurement of plasma nitrite by chemiluminescence. *Methods Mol Biol.* **610**, 41–49 (2010).
37. Kowaluk, E. A. & Fung, H. L. Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. *J. Pharmacol. Exp. Ther.* **255**, 1256–1264 (1990).
38. Mengel, A., Chaki, M., Shekariesfahlan, A. & Lindermayr, C. Effect of nitric oxide on gene transcription—S-nitrosylation of nuclear proteins. *Front. Plant Sci.* **4**, 293 (2013).
39. Grün, S., Lindermayr, C., Sell, S. & Durner, J. Nitric oxide and gene regulation in plants. *J. Exp. Bot.* **57**, 507–516 (2006).
40. Schachter, T. N., Shen, T., Liu, Y. & Schneider, M. F. Kinetics of nuclear-cytoplasmic translocation of Foxo1 and Foxo3A in adult skeletal muscle fibers. *Am. J. Physiol. Cell Physiol.* **303**, C977–990 (2012).
41. Massion, P. B., Feron, O., Dessy, C. & Balligand, J. L. Nitric oxide and cardiac function: ten years after, and continuing. *Circ. Res.* **93**, 388–398 (2003).
42. Shah, A. M. & MacCarthy, P. A. Paracrine and autocrine effects of nitric oxide on myocardial function. *Pharmacol. Ther.* **86**, 49–86 (2000).
43. Hare, J. M., Givertz, M. M., Creager, M. A. & Colucci, W. S. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of β -adrenergic inotropic responsiveness. *Circulation* **97**, 161–166 (1998).
44. Ishikawa, K. *et al.* Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. *Secondary Prev. Group. Jpn Circ J.* **60**, 779–788 (1996).
45. Kojima, S. *et al.* Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. *Circ. J.* **71**, 301–307 (2007).
46. Tsujimoto, T. & Kajio, H. Use of nitrates and risk of cardiovascular events in patients with heart failure with preserved ejection fraction. *Mayo Clin Proc.* **94**, 1210–1220 (2019).
47. Wang, Y. *et al.* Transcription factors Csx/Nkx25 and GATA4 distinctly regulate expression of Ca²⁺ channels in neonatal rat heart. *J. Mol. Cell Cardiol.* **42**, 1045–1053 (2007).
48. Kang, L. *et al.* Bepridil up-regulates cardiac Na⁺ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity. *Br. J. Pharmacol.* **157**, 404–414 (2009).
49. Masuda, K. *et al.* Testosterone-mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats. *J. Physiol. Sci.* **68**, 759–767 (2018).
50. Wang, Y. *et al.* Binge alcohol exposure triggers atrial fibrillation through T-type Ca²⁺ channel upregulation via protein kinase C (PKC)/glycogen synthesis kinase 3 β (GSK3 β)/nuclear factor of activated T-cells (NFAT) signaling—an experimental account of holiday heart syndrome. *Circ. J.* **84**, 1931–1940 (2020).
51. Morishima, M., Horikawa, K. & Funaki, M. Cardiomyocytes cultured on mechanically compliant substrates, but not on conventional culture devices, exhibit prominent mitochondrial dysfunction due to reactive oxygen species and insulin resistance under high glucose. *PLoS ONE* **13**, e0201891 (2018).

Acknowledgements

This work was supported in part by JSPS KAKEN 25460292 (K.O.) from the Japan Society for the Promotion of Science, Tokyo.

Author contributions

M.Z., G.L. and K.O. designed the study. P.W., M.W., and X.Z. performed patch-clamp experiments. M.M. performed molecular biological experiments. Y.L., K.Y., S.K., and T.K. analyzed the data. K.O. drew the image of schematic illustration (Fig. 8). P.W. and K.O. wrote the manuscript. All authors interpreted the data.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-90840-0>.

Correspondence and requests for materials should be addressed to K.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021